Haemalogix

About

HaemaLogiX develops monoclonal antibody immunotherapies for multiple myeloma and other blood cancers, advancing KappaMab manufacturing and clinical development with planned higher-dose and lambda-directed studies.

Mission

HaemaLogiX develops monoclonal antibodies (KappaMab) and immune-oncology therapies targeting multiple myeloma and other blood cancers. The company is led by Bryce Carmine, Chairman and CEO. Its core program is KappaMab, with manufacturing and clinical development underway. HaemaLogiX plans a higher-dose 30 mg/kg monotherapy study and is preparing two further studies. It also intends to progress an antibody for lambda-type multiple myeloma, which accounts for roughly 30% of patients. The company recently raised funding to support manufacturing of the next Kappa antibody batch and continued clinical activities, with final Phase IIb results expected in late 2021.

Quick Facts